AUPH
$20.21
Aurinia Pharm Ord
$1.06
5.54%
AUPH
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.25)
Revenue:  $22.77 Mil
Wednesday
Feb 2
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AUPH reports earnings?
Beat
Meet
Miss

Where is AUPH's stock price going from here?
Up
Flat
Down
Stock chart of AUPH
Analysts
Summary of analysts' recommendations for AUPH
Score
Grade
Pivots
Resistance
$21.92
$20.62
$19.89

$18.59

Support
$17.86
$16.56
$15.83
Tweet
Growth
Description
Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbInterCeptPfizer